Puma Biotechnology stock
PBYINASDAQPuma Biotechnology, Inc., HealthcareISIN US74587V1070
61Score 61 out of 100, Neutral
Price and trend
49 / 100
Price history
+62% in one yearThe chart shows daily closes over 15 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 0.6% above it.
Since March 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 17).
The price is 28% below its 52-week high. Largest decline in 15 years: 99% (September 2014 to May 2022).
Chart figures for advanced users
- SMA 50$9.79
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$8.03
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)17
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.84
- The lowest closing price of the last twelve months.
- Resistance$11.26
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Puma Biotechnology, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $417.09M, is number 261 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $228.37M (down 0.9% year on year) and earnings of $31.11M (up 2.8%).
- MEQIRI Score 61 out of 100 (Neutral): rank 269 of 714 in Healthcare, median 53.
Show more
- The P/E is 18 (Biotechnology median 21.3, own median of recent years 9.4).
- Our model puts fair value at $18.25, with the price 56% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 51.2% in fiscal 2025, Biotechnology median −24.3%.Profitability 80
- Below fair valuePrice 56% below the fair value of $18.25.Valuation 90
- More cash than debtCash $97.53M, financial debt $28.55M (fiscal 2025).Stability 67
Weaknesses
- DilutionShare count up 26% since 2020.Capital allocation 54
- Volatile share priceVolatility 52% a year over the last 12 months.Stability 67
Its standout strengths are valuation and profitability, while technical analysis and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $13.03 and expensive above $30.41 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $26.92 (cash-flow model) and $9.57 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $16.03, at 8.2% it would be $21.48.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 9.4% on the twelve months before. Revenue turned from negative at the start of the period to positive ($228.37M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 75%, operating 16%, net 14%.
Debt & balance sheet
Fiscal 2025Low debt, and interest is adequately covered.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported $0.15 (expected $0.09)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.380.0%
- Revenue
- $226M0.0%
- Earnings per share
- $0.200.0%
- Revenue
- $229M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +11.5%2026 guidance raised: net NERLYNX revenue of $205 million to $209 million (previously $202 million to $206 million) and net income of $17 million to $20 million (previously $16 million to $19 million).
“For fiscal year 26, Puma anticipates that net NERLYNX product revenue will be in the range of $205 million to $209 million higher than our prior guidance of $202 million to $206 million We also anticipate that our gross to net adjustment for the full year 2026 will be between 26.5% and 27.5%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 9 insiders sold, $1.7M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Wilson Troy EdwardSale
14 Sept 2026, Board
- Shares
- 5,000
- Price
- $9.10
- Value
- $45,500
- Cesano AlessandraSale
14 Sept 2026, Board
- Shares
- 62,150
- Price
- $9.12
- Value
- $566,994
- Auerbach Alan HSale
6 Jul 2026, 10 percent owner, officer: President and CEO
- Shares
- 44,058
- Price
- $8.26
- Value
- $364,051
Show 7 more
- Hunt Douglas MSale
6 Jul 2026, See Remarks
- Shares
- 8,460
- Price
- $8.26
- Value
- $69,905
- Nougues Maximo FSale
6 Jul 2026, Chief Financial Officer
- Shares
- 9,386
- Price
- $8.26
- Value
- $77,557
- Wilson Troy EdwardSale
12 Jun 2026, Board
- Shares
- 10,800
- Price
- $7.20
- Value
- $77,748
- Stuglik Brian MSale
12 Jun 2026, Board
- Shares
- 8,100
- Price
- $7.20
- Value
- $58,311
- Senderowicz AdrianSale
12 Jun 2026, Board
- Shares
- 27,000
- Price
- $7.20
- Value
- $194,311
- Moyes Jay MSale
12 Jun 2026, Board
- Shares
- 22,000
- Price
- $7.22
- Value
- $158,796
- Dorval AllisonSale
12 Jun 2026, Board
- Shares
- 11,610
- Price
- $7.20
- Value
- $83,579
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Puma Biotechnology
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Benitec BiopharmaBNTC $440.91M31
- YD BioYDES $435.61M40
- Tectonic TherapeuticTECX $429.3M34
- RezoluteRZLT $426.45M37
- Lyell ImmunopharmaLYEL $414.51M33
- Contineum TherapeuticsCTNM $413.46M35
- CorMedixCRMD $413.1M59
- X4 PharmaceuticalsXFOR $408.67M37
ETFs that hold Puma Biotechnology
Held by 4 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.04% | 0.39% | €1.47B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.04% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
Show 1 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.